UPDATE 1-AstraZeneca's motavizumab faces delay at US FDA Reuters - The Anglo-Swedish drugmaker said on Friday it had received a so-called "complete response letter" from the US Food and Drug Administration ( FDA ) asking for ...

Duke doctor mentioned for FDA post CharlotteObserver.com, NC - The respected Duke University cardiologist and head of the Duke Clinical Research Institute is among people mentioned as possible candidates for FDA ...

Washington Post Canadian Health Officials, Echoing the FDA , Determine Infant ... Wall Street Journal - Earlier this week, controversy arose in the US when the FDA said tests showed that a few infant formula products available in the US contained traces of ... FDA Draws Fire Over Chemicals In Baby Formula Transform the FDA FDA finds melamine traces in US infant formulas -

Health Highlights: Nov. 27, 2008 Washington Post, United States - The recall was prompted by the FDA after a lab analysis found the product to contain undeclared sibutramine, making it an unapproved drug. ... Health Highlights: Nov. 26, 2008

Arpida to Restructure and Focus on Key Projects MarketWatch - The company says this is to be seen as a consequence of the negative recommendation of the US Food and Drug Administration ( FDA ) advisory board on 20 ... UPDATE 1-Arpida slashes jobs after key drug setback Arpida To Cut Costs, Staff As It Tries To Rekindle Iclaprim UPDATE 1-Arpida shares rally on job cut plans

The Star-Ledger - NJ.com Basilea stock up 20 pct, FDA blow selloff overdone Forbes, NY - 'After the FDA response letter for ceftobiprole, Basilea lost some 36 percent. This is far too much and has nothing to do with the magnitude of the letter. ... 2nd UPDATE: Basilea Drug Ceftobiprole Faces Renewed FDA Delay FDA rejects Johnson & Johnson infection treatment UPDATE 2- FDA delays J&J, Basilea antibiotic approval -

FDA Asks Sun Pharma To Resubmit Antidepressant Application CNNMoney.com - BANGALORE -(Dow Jones)- India's Sun Pharmaceutical Industries Ltd. (524715.BY) Thursday said the US Food and Drug Administration has asked it to resubmit ...

Sanofi Heart Drug Faces FDA Hearing, Further Delay (Update1) Bloomberg - Priority review status generally means the FDA makes a decision within six months. Frances largest drugmaker, which is replacing Chief Executive Officer ... Sanofi must wait until March for FDA's review on Multaq Sanofi's Heart Drug Multaq Set To Face FDA Mtg In March UPDATE 1-Sanofi's Multaq to get US panel review in March

Watson Pharmaceuticals Receives FDA Final Approval for Generic ... MarketWatch - ... difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, ... Watson says FDA approves its generic Wellbutrin XL Watson wins FDA approval for generic depression drug Watson's generic Wellbutrin gets final FDA approval -

Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan ... MarketWatch - The lawsuit is based upon Abbreviated New Drug Applications (ANDAs) filed by Mylan and Barr, each seeking US Food and Drug Administration ( FDA ) approval for ... Barr confirms patent challenge of Amrix extended-release capsules Cephalon sues generic companies over patents Barr Pharma. confirms challenge of patent listed by Anesta in ... -